|This article needs additional citations for verification. (October 2008) (Learn how and when to remove this template message)|
Thrombogenicity refers to the tendency of a material in contact with the blood to produce a thrombus, or clot. It not only refers to fixed thrombi but also to emboli, thrombi which have become detached and travel through the bloodstream. Thrombogenicity can also encompass events such as the activation of immune pathways and the complement system. All materials are considered to be thrombogenic with the exception of the normal state of endothelial cells which line blood vessels. Certain medical implants appear non-thrombogenic due to high flow rates of blood past the implant, but in reality all are thrombogenic to a degree. Various surface treatments are available to minimize these thrombogenic effects.
A thrombogenic implant will eventually be covered by a fibrous capsule, the thickness of this capsule can be considered one measure of thrombogenicity, and if extreme can lead to the failure of the implant.
- "Terminology for biorelated polymers and applications (IUPAC Recommendations 2012)" (PDF). Pure and Applied Chemistry. 84 (2): 377–410. 2012. doi:10.1351/PAC-REC-10-12-04.
- López JA, Chen J (2009). "Pathophysiology of venous thrombosis". Thromb Res. 123 (Suppl 4): S30–4. PMID 19303501. doi:10.1016/S0049-3848(09)70140-9.
- Paul, R; Marseille, O; Hintze, E; Huber, L; Schima, H; Reul, H; Rau, G (1998). "In vitro thrombogenicity testing of artificial organs". The International journal of artificial organs. 21 (9): 548–52. PMID 9828061.
- Kenny, DA; Berger, K; Walker, MW; Robel, SB; Boguslavsky, L; Ray, LI; Lischko, MM; Sauvage, LR (1980). "Experimental comparison of the thrombogenicity of fibrin and PTFE flow surfaces.". Annals of Surgery. 191 (3): 355–61. PMC . PMID 6444800. doi:10.1097/00000658-198003000-00016.
|This medical article is a stub. You can help Wikipedia by expanding it.|